The House Oversight and Government Reform Committee is summoning Mylan CEO Heather Bresch to explain the company’s pricing practices for its EpiPen auto injector device.
“Mylan has a virtual monopoly over the epinephrine auto-injector market,” an Aug. 29 letter to the CEO says. “While the medicine that actually stops an adverse reaction is remarkably cheap – only a few cents per dose – it is the delivery mechanism that is breaking the bank of Americans,” says the letter signed by Committee Chairman Jason Chaffetz and Ranking Member Elijah Cummings says.
The price for a two-pack of the epinephrine auto injector has increased to $600, a nearly 400-percent increase over the last decade.
The congressmen requested the company to provide within two weeks the following documents: